Mankind to use debt, internal accruals to fund BSV buyout

Mankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix of debt and equity. This strategic move will make them leaders in the gynaecology-fertility segment. The acquisition aligns with their goal to expand in high-potential areas and is expected to boost earnings from the second year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kS16e2Z
via IFTTT